Commonwealth Equity Services, LLC Affimed N.V. Transaction History

Commonwealth Equity Services, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 06, 2024	BUY	$0.32 - $0.62 $47,540 - $92,109	148,563 Added 264.37%	204,759 $128,000
Q3 2023 Oct 23, 2023	SELL	$0.46 - $0.65 $1,150 - $1,625	-2,500 Reduced 4.26%	56,196 $27,000
Q2 2023 Aug 10, 2023	BUY	$0.57 - $1.08 $2,849 - $5,400	5,000 Added 9.31%	58,696 $35,000
Q1 2023 May 11, 2023	SELL	$0.66 - $1.29 $3,379 - $6,604	-5,120 Reduced 8.71%	53,696 $40,000
Q4 2022 Feb 07, 2023	BUY	$1.1 - $2.45 $3,043 - $6,779	2,767 Added 4.94%	58,816 $72,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $490 - $830	250 Added 0.45%	56,049 $115,000
Q2 2022 Jul 19, 2022	BUY	$2.27 - $4.86 $31,655 - $67,772	13,945 Added 33.32%	55,799 $154,000
Q1 2022 May 04, 2022	BUY	$3.69 - $5.65 $39,464 - $60,426	10,695 Added 34.32%	41,854 $182,000
Q4 2021 Jan 31, 2022	BUY	$5.37 - $7.07 $167,323 - $220,294	31,159 New	31,159 $172,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

Stay updated on Commonwealth Equity Services, LLC with notifications on news.